Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | STS | P08842 | 1/20 | 0.53 |
| ▸ | GPR119 | Q8TDV5 | 3/20 | 0.53 |
| ▸ | JAK2 | O60674 | 1/20 | 0.53 |
| ▸ | JAK1 | P23458 | 1/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | PKM | P14618 | 1/20 | 0.50 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.50 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | TACR1 | P25103 | 1/20 | 0.48 |
| ▸ | USP30 | Q70CQ3 | 4/20 | 0.47 |
| ▸ | ACHE | P22303 | 1/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
| ▸ | TP53 | P04637 | 2/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | THRB | P10828 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2252656 | 1.00 | STS (0.53) | STSGPR119JAK2JAK1KDM4E | |
| SCHEMBL2253056 | 1.00 | STS (0.53) | STSGPR119JAK2JAK1KDM4E | |
| SCHEMBL5477496 | 0.92 | GPR119 (0.52) | STSGPR119JAK2JAK1KDM4E | |
| SCHEMBL556613 | 0.92 | GPR119 (0.52) | STSGPR119JAK2JAK1KDM4E | |
| SCHEMBL5477485 | 0.92 | GPR119 (0.52) | STSGPR119JAK2JAK1KDM4E | |
| SCHEMBL12281464 | 0.91 | STS (0.53) | STSGPR119JAK2JAK1KDM4E | |
| SCHEMBL12131760 | 0.91 | STS (0.53) | STSGPR119JAK2JAK1KDM4E | |
| SCHEMBL29643908 | 0.91 | STS (0.53) | STSGPR119JAK2JAK1KDM4E | |
| SCHEMBL707351 | 0.91 | USP30 (0.51) | STSGPR119JAK2JAK1KDM4E | |
| SCHEMBL707352 | 0.91 | USP30 (0.51) | STSGPR119JAK2JAK1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2935263-B1 | SUBSTITUTED IMIDAZOPYRIDINES AS HDM2 INHIBITORS | MERCK SHARP & DOHME (US) | 2018-12-05 | — | — | EP | disclosed |
| EP-2935263-A1 | SUBSTITUTED IMIDAZOPYRIDINES AS HDM2 INHIBITORS | Merck Sharp & Dohme Corp. (US) | 2015-10-28 | — | — | EP | disclosed |
| US-8962611-B2 | Substituted imidazopyridines as HDM2 inhibitors | MERCK SHARP & DOHME CORP. (US) | 2015-02-24 | — | — | US | disclosed |
| US-20140357618-A1 | SUBSTITUTED IMIDAZOPYRIDINES AS HDM2 INHIBITORS | MERCK SHARP & DOHME LLC | 2014-12-04 | — | — | US | disclosed |
| US-8846657-B2 | Substituted imidazopyridines as HDM2 inhibitors | MERCK SHARP & DOHME CORP. (US) | 2014-09-30 | — | — | US | disclosed |
| WO-2014100065-A1 | SUBSTITUTED IMIDAZOPYRIDINES AS HDM2 INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2014-06-26 | — | — | WO | disclosed |
| US-20140179680-A1 | Substituted Imidazopyridines as HDM2 Inhibitors | MERCK SHARP & DOHME LLC | 2014-06-26 | — | — | US | disclosed |
| EP-2537845-B1 | 6H-DIBENZO[B,E]OXEPINE DERIVED NONSTEROIDAL MINERALOCORTICOID RECEPTOR ANTAGONISTS | LILLY CO ELI (US) | 2014-03-19 | — | — | EP | disclosed |
| EP-2537845-B1 | 6H-DIBENZO[B,E]OXEPINE DERIVED NONSTEROIDAL MINERALOCORTICOID RECEPTOR ANTAGONISTS | LILLY CO ELI (US) | 2014-03-19 | — | — | EP | disclosed |
| EP-2298769-B1 | Xanthin derivatives, their production and utilisation as medicine | BOEHRINGER INGELHEIM PHARMA (DE) | 2013-10-30 | — | — | EP | disclosed |
| US-20090163472-A1 | MINERALOCORTICOID RECEPTOR ANTAGONISTS AND METHODS OF USE | ELI LILLY AND COMPANY | 2009-06-25 | — | — | US | disclosed |
| EP-1757606-B1 | Xanthinderivatives for use as medical agents and the preparation thereof | BOEHRINGER INGELHEIM PHARMA (DE) | 2009-05-06 | — | — | EP | disclosed |
| EP-1953162-A1 | Xanthin derivatives, their production and utilisation as medicine | Boehringer Ingelheim Pharma GmbH & Co. KG (DE) | 2008-08-06 | — | — | EP | disclosed |
| US-20070244133-A1 | Thienopyrimidines and Thiazolopyrimidines for Use in Medicine | ASTRAZENECA AB (SE) | 2007-10-18 | — | — | US | disclosed |
| EP-1757606-A1 | Xanthinderivatives, preparation thereof and their use as medical agents | Boehringer Ingelheim Pharma GmbH & Co. KG (DE) | 2007-02-28 | — | — | EP | disclosed |
| EP-1368349-B1 | XANTHINE DERIVATIVE, PRODUCTION AND USE THEREOF AS A MEDICAMENT | BOEHRINGER INGELHEIM PHARMA (DE) | 2007-02-14 | — | — | EP | disclosed |
| US-20060205711-A1 | Xanthine derivatives, the preparation thereof and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2006-09-14 | — | — | US | disclosed |
| US-20040077645-A1 | Dipeptidyl aminopeptidase inhibitors; diabetes mellitus, arthritis, obesity, allograft transplantation and osteoporosis treatment | BOEHRINGER INGELHEIM PHARMA GMBH & CO KG (DE) | 2004-04-22 | — | — | US | disclosed |
| EP-1368349-A1 | XANTHINE DERIVATIVE, PRODUCTION AND USE THEREOF AS A MEDICAMENT | Boehringer Ingelheim Pharma GmbH & Co.KG (DE) | 2003-12-10 | — | — | EP | disclosed |
| WO-2002068420-A1 | XANTHINE DERIVATIVE, PRODUCTION AND USE THEREOF AS A MEDICAMENT | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2002-09-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140179680-A1 | Substituted Imidazopyridines as HDM2 Inhibitors | DDX21, ING2, MDM2 | STS 2898/4885GPR119 4505/4885JAK2 2579/4885 |
| US-20090163472-A1 | MINERALOCORTICOID RECEPTOR ANTAGONISTS AND METHODS OF USE | NR3C2, MC2R, REN | STS 569/4885GPR119 33/4885JAK2 1625/4885 |
| US-20060205711-A1 | Xanthine derivatives, the preparation thereof and their use as pharmaceutical compositions | DPP4, DPP3, DPP7 | STS 1067/4885GPR119 159/4885JAK2 2142/4885 |
| US-20070244133-A1 | Thienopyrimidines and Thiazolopyrimidines for Use in Medicine | CXCR4, CXCR1, CXCR3 | STS 1113/4885GPR119 1153/4885JAK2 179/4885 |
| US-20140357618-A1 | SUBSTITUTED IMIDAZOPYRIDINES AS HDM2 INHIBITORS | DDX21, ING2, MDM2 | STS 2898/4885GPR119 4505/4885JAK2 2579/4885 |
| US-20040077645-A1 | Dipeptidyl aminopeptidase inhibitors; diabetes mellitus, arthritis, obesity, allograft transplantation and osteoporosis treatment | DPP4, DPP3, DPP7 | STS 867/4885GPR119 60/4885JAK2 1545/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.